Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 23374145)

1.

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C.

Immunology. 2013 Jul;139(3):377-85. doi: 10.1111/imm.12087.

2.

Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.

De Keersmaecker B, Allard SD, Lacor P, Schots R, Thielemans K, Aerts JL.

J Virol. 2012 Sep;86(17):9351-60. doi: 10.1128/JVI.00472-12. Epub 2012 Jun 20.

3.

Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.

Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y.

Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8.

PMID:
19818504
4.

Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses.

Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Saeland E, van Kooyk Y.

Int J Cancer. 2011 Mar 15;128(6):1371-83. doi: 10.1002/ijc.25458.

PMID:
20473945
5.

TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.

Crespo MI, Zacca ER, Núñez NG, Ranocchia RP, Maccioni M, Maletto BA, Pistoresi-Palencia MC, Morón G.

J Immunol. 2013 Feb 1;190(3):948-60. doi: 10.4049/jimmunol.1102725. Epub 2013 Jan 2.

6.

A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.

Hunzeker JT, Elftman MD, Mellinger JC, Princiotta MF, Bonneau RH, Truckenmiller ME, Norbury CC.

J Immunol. 2011 Jan 1;186(1):183-94. doi: 10.4049/jimmunol.1001737. Epub 2010 Nov 22.

7.

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG.

Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. doi: 10.1007/s00262-008-0620-4. Epub 2008 Nov 14.

PMID:
19009291
9.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
11.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

12.

Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.

Periasamy P, O'Neill HC.

Exp Hematol. 2013 Mar;41(3):281-92. doi: 10.1016/j.exphem.2012.11.003. Epub 2012 Nov 23.

PMID:
23178375
13.

Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.

Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC.

J Immunol. 2010 Sep 15;185(6):3426-35. doi: 10.4049/jimmunol.1001205. Epub 2010 Aug 20.

14.

Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.

Smyth LA, Hervouet C, Hayday T, Becker PD, Ellis R, Lechler RI, Lombardi G, Klavinskis LS.

J Immunol. 2012 Sep 1;189(5):2274-82. doi: 10.4049/jimmunol.1200664. Epub 2012 Jul 20.

15.
16.

Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.

Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF.

J Immunol. 2009 Dec 15;183(12):7732-42. doi: 10.4049/jimmunol.0902707. Epub .

17.

β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.

Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I, Jiang A.

J Leukoc Biol. 2014 Jan;95(1):179-90. doi: 10.1189/jlb.0613330. Epub 2013 Sep 10.

18.

Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1.

Klotz L, Hucke S, Thimm D, Classen S, Gaarz A, Schultze J, Edenhofer F, Kurts C, Klockgether T, Limmer A, Knolle P, Burgdorf S.

J Immunol. 2009 Jul 1;183(1):129-36. doi: 10.4049/jimmunol.0804260. Epub 2009 Jun 17.

19.

LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells.

Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, Ramoni C, Filesi I, Biocca S, Gabriele L, Belardelli F.

Blood. 2010 Feb 25;115(8):1554-63. doi: 10.1182/blood-2009-07-234468. Epub 2009 Dec 15.

20.

Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells.

Lee YH, Lee YR, Kim KH, Im SA, Song S, Lee MK, Kim Y, Hong JT, Kim K, Lee CK.

Int Immunopharmacol. 2011 Aug;11(8):985-91. doi: 10.1016/j.intimp.2011.02.013. Epub 2011 Feb 24.

PMID:
21354357
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk